Forte (FBRX) Posts Dismal Data on Atopic Dermatitis Candidate

Published on September 3, 2021

Forte's (FBRX) mid-stage study on its lead candidate FB-401 to address the condition of atopic dermatitis fails to meet its primary goal and the compa...